The US pharmaceutical industry has enjoyed phenomenal success--13% annual growth in the past 5 years in the face of challenges from a variety of sources, including generic competition and mounting managed-care cost pressures. To drive this growth, the industry has engaged in an increasingly intense commercialization arms race, nearly doubling the number of sales reps on the street since 1995. While this sales model has worked well for several decades, there is growing evidence that it is missing the mark for the many high prescribing physicians. Results of a recent McKinsey & Company initiative on sales excellence in US pharmaceuticals reveals that drug companies can benefit from revisiting their traditional sales model, with potentially big advantages for those who shape the emerging approach. And whether the objective is near term revenue growth or leading the industry in a strategic shift, most pharmaceutical companies can benefit from pursuing five key actions to drive sales excellence.
By Martin Elling, Holly Fogle, Teri Lawver, Charles McKhann, and
Christopher Simon
The pharmaceutical industry has demonstrated a remarkable ability to manage effectively through change and to thrive. Collectively the industry has improved patient care and achieved top-line annual sales growth of...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.
The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.
Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.
From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.
Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.
